DK1383507T3 - Anvendelse af galanthamin til behandling af sygdomssymptomer i det centrale nervesystem på grund af intoxikationer med psykotrope substanser - Google Patents

Anvendelse af galanthamin til behandling af sygdomssymptomer i det centrale nervesystem på grund af intoxikationer med psykotrope substanser

Info

Publication number: DK1383507T3
Authority: DK; Denmark
Prior art keywords: intoxications; galanthamine; treatment; nervous system; central nervous
Prior art date: 2001-04-24

Application number

DK02764017T

Other languages

English (en)

Inventor

Klaus Opitz

Joachim Moormann

Thomas Hille

Frank Becher

Original Assignee

Hf Arzneimittelforsch Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-24

Filing date

2002-04-18

Publication date

2008-03-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7682409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1383507(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-04-18 Application filed by Hf Arzneimittelforsch Gmbh filed Critical Hf Arzneimittelforsch Gmbh

2008-03-17 Application granted granted Critical

2008-03-17 Publication of DK1383507T3 publication Critical patent/DK1383507T3/da

Links

ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 title 2
HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 title 1
LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 title 1
208000015114 central nervous system disease Diseases 0.000 title 1
229960003980 galantamine Drugs 0.000 title 1
BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 title 1
ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 title 1
231100000566 intoxication Toxicity 0.000 title 1
230000035987 intoxication Effects 0.000 title 1
IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 title 1
230000000506 psychotropic effect Effects 0.000 title 1
239000000126 substance Substances 0.000 title 1
208000024891 symptom Diseases 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Addiction (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Psychiatry (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

DK02764017T 2001-04-24 2002-04-18 Anvendelse af galanthamin til behandling af sygdomssymptomer i det centrale nervesystem på grund af intoxikationer med psykotrope substanser DK1383507T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE10119862A DE10119862A1 (de)	2001-04-24	2001-04-24	Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen
PCT/EP2002/004277 WO2002085370A1 (de)	2001-04-24	2002-04-18	Verwendung von galanthamin zur behandlung von krankheitserscheinungen des zentralen nervensystems aufgrund von intoxikationen mit psychotropen substanzen

Publications (1)

Publication Number	Publication Date
DK1383507T3 true DK1383507T3 (da)	2008-03-17

Family

ID=7682409

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02764017T DK1383507T3 (da)	2001-04-24	2002-04-18	Anvendelse af galanthamin til behandling af sygdomssymptomer i det centrale nervesystem på grund af intoxikationer med psykotrope substanser

Country Status (26)

Country	Link
US (1)	US8207159B2 (da)
EP (1)	EP1383507B1 (da)
JP (1)	JP2004531533A (da)
KR (1)	KR20040005934A (da)
CN (1)	CN100400043C (da)
AR (1)	AR033468A1 (da)
AT (1)	ATE378052T1 (da)
AU (1)	AU2002308148B2 (da)
BR (1)	BR0209126A (da)
CA (1)	CA2444818C (da)
CZ (1)	CZ20032789A3 (da)
DE (2)	DE10119862A1 (da)
DK (1)	DK1383507T3 (da)
EA (1)	EA200301135A1 (da)
ES (1)	ES2296990T3 (da)
HU (1)	HUP0401123A3 (da)
IL (2)	IL158382A0 (da)
MX (1)	MXPA03009765A (da)
NO (1)	NO20034740D0 (da)
NZ (1)	NZ529004A (da)
PL (1)	PL207525B1 (da)
PT (1)	PT1383507E (da)
SK (1)	SK287235B6 (da)
TW (1)	TWI329512B (da)
WO (1)	WO2002085370A1 (da)
ZA (1)	ZA200308004B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2004216360B2 (en) *	2003-02-27	2009-09-17	Eisai R & D Management Co., Ltd.	Pharmaceutical composition for treatment of drug dependence
DE10338544B4 (de) *	2003-08-19	2017-08-31	Janssen Pharmaceutica N.V.	Buccale Formulierungen des Galanthamins und deren Anwendungen
FR2930891B1 (fr)	2008-05-06	2010-09-24	Biocodex	Composes anti-amnesiants et compositions pharmaceutiques les comprenant
EP2586436A1 (en) *	2011-10-31	2013-05-01	Commissariat à l'Énergie Atomique et aux Énergies Alternatives	Use of anti-connexin agents for enhancing the therapeutic effect of acetylcholinesterase inhibitor
WO2016187339A1 (en) *	2015-05-18	2016-11-24	Synaptec Development Llc	GALANTAMINE CLEARANCE OF AMYLOIDß
WO2023168023A1 (en)	2022-03-04	2023-09-07	Reset Pharmaceuticals, Inc.	Co-crystals or salts comprising psilocin

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1193061B (de)	1961-12-20	1965-05-20	Vni Chimiko Pharmazewtitschesk	Verfahren zur Gewinnung von Galanthamin-hydrobromid aus Pflanzen der Familie der Amaryllidaceen
US3797494A (en)	1969-04-01	1974-03-19	Alza Corp	Bandage for the administration of drug by controlled metering through microporous materials
US3996934A (en)	1971-08-09	1976-12-14	Alza Corporation	Medical bandage
US3742951A (en)	1971-08-09	1973-07-03	Alza Corp	Bandage for controlled release of vasodilators
US4031894A (en)	1975-12-08	1977-06-28	Alza Corporation	Bandage for transdermally administering scopolamine to prevent nausea
DE3315272C2 (de)	1983-04-27	1986-03-27	Lohmann Gmbh & Co Kg, 5450 Neuwied	Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
US4666829A (en) *	1985-05-15	1987-05-19	University Of California	Polypeptide marker for Alzheimer's disease and its use for diagnosis
US6150354A (en) *	1987-01-15	2000-11-21	Bonnie Davis	Compounds for the treatment of Alzheimer's disease
DE3843239C1 (da)	1988-12-22	1990-02-22	Lohmann Therapie Syst Lts
US5015645A (en) *	1989-10-19	1991-05-14	Ciba-Geigy Corporation	Tetracyclic pyrrole lactam derivatives
DE4010079A1 (de) *	1990-03-29	1991-10-02	Lohmann Therapie Syst Lts	Pharmazeutische formulierung zur behandlung des alkoholismus
US5519017A (en) *	1990-03-29	1996-05-21	Lts Lohmann Therapie-Systeme Gmbh + Co. Kg	Pharmaceutic formulation for the treatment of alcoholism
US5336675A (en) *	1991-05-14	1994-08-09	Ernir Snorrason	Method of treating mania in humans
DE4301782C1 (de) *	1993-01-23	1994-08-25	Lohmann Therapie Syst Lts	Verwendung von Galanthamin zur Behandlung der Nicotinabhängigkeit
DE19509663A1 (de)	1995-03-17	1996-09-19	Lohmann Therapie Syst Lts	Verfahren zur Isolierung von Galanthamin
AU4078997A (en) *	1996-08-22	1998-03-06	New York University	Cholinesterase inhibitors for treatment of parkinson's disease
US5932557A (en) *	1997-08-12	1999-08-03	Mustafa; S. Jamal	Adenosine A1 receptor antisense oligonucleotide treatment of alcohol and marijuana-induced psychomotor impairments
WO2001032115A1 (en) *	1999-11-04	2001-05-10	Xel Herbaceuticals	Transdermal administration of huperzine
US20020151591A1 (en) *	2000-10-17	2002-10-17	Anabella Villalobos	Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders

2001
- 2001-04-24 DE DE10119862A patent/DE10119862A1/de not_active Withdrawn
2002
- 2002-04-18 CN CNB028088905A patent/CN100400043C/zh not_active Expired - Lifetime
- 2002-04-18 PL PL366840A patent/PL207525B1/pl not_active IP Right Cessation
- 2002-04-18 CA CA002444818A patent/CA2444818C/en not_active Expired - Lifetime
- 2002-04-18 NZ NZ529004A patent/NZ529004A/en unknown
- 2002-04-18 EA EA200301135A patent/EA200301135A1/ru unknown
- 2002-04-18 AT AT02764017T patent/ATE378052T1/de active
- 2002-04-18 AU AU2002308148A patent/AU2002308148B2/en not_active Ceased
- 2002-04-18 EP EP02764017A patent/EP1383507B1/de not_active Expired - Lifetime
- 2002-04-18 HU HU0401123A patent/HUP0401123A3/hu unknown
- 2002-04-18 US US10/475,357 patent/US8207159B2/en not_active Expired - Fee Related
- 2002-04-18 MX MXPA03009765A patent/MXPA03009765A/es active IP Right Grant
- 2002-04-18 IL IL15838202A patent/IL158382A0/xx unknown
- 2002-04-18 JP JP2002582943A patent/JP2004531533A/ja active Pending
- 2002-04-18 CZ CZ20032789A patent/CZ20032789A3/cs unknown
- 2002-04-18 DE DE50211207T patent/DE50211207D1/de not_active Expired - Lifetime
- 2002-04-18 PT PT02764017T patent/PT1383507E/pt unknown
- 2002-04-18 WO PCT/EP2002/004277 patent/WO2002085370A1/de not_active Ceased
- 2002-04-18 KR KR10-2003-7013971A patent/KR20040005934A/ko not_active Ceased
- 2002-04-18 ES ES02764017T patent/ES2296990T3/es not_active Expired - Lifetime
- 2002-04-18 DK DK02764017T patent/DK1383507T3/da active
- 2002-04-18 BR BR0209126-7A patent/BR0209126A/pt not_active Application Discontinuation
- 2002-04-18 SK SK1315-2003A patent/SK287235B6/sk not_active IP Right Cessation
- 2002-04-22 TW TW091108204A patent/TWI329512B/zh not_active IP Right Cessation
- 2002-04-24 AR ARP020101482A patent/AR033468A1/es unknown
2003
- 2003-10-13 IL IL158382A patent/IL158382A/en active IP Right Grant
- 2003-10-15 ZA ZA200308004A patent/ZA200308004B/en unknown
- 2003-10-23 NO NO20034740A patent/NO20034740D0/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
BR0209126A (pt)	2004-07-27
ZA200308004B (en)	2004-02-11
IL158382A (en)	2009-09-01
DE50211207D1 (de)	2007-12-27
PT1383507E (pt)	2008-02-20
ES2296990T3 (es)	2008-05-01
CN100400043C (zh)	2008-07-09
JP2004531533A (ja)	2004-10-14
AU2002308148B2 (en)	2006-11-02
EP1383507A1 (de)	2004-01-28
WO2002085370A1 (de)	2002-10-31
MXPA03009765A (es)	2005-04-19
CA2444818C (en)	2009-06-16
CZ20032789A3 (en)	2004-05-12
CN1505516A (zh)	2004-06-16
US20040116406A1 (en)	2004-06-17
PL207525B1 (pl)	2010-12-31
EP1383507B1 (de)	2007-11-14
SK13152003A3 (sk)	2004-04-06
NZ529004A (en)	2007-01-26
DE10119862A1 (de)	2002-11-07
NO20034740L (no)	2003-10-23
PL366840A1 (en)	2005-02-07
CA2444818A1 (en)	2002-10-31
NO20034740D0 (no)	2003-10-23
EA200301135A1 (ru)	2004-04-29
KR20040005934A (ko)	2004-01-16
HK1062401A1 (zh)	2004-11-05
HUP0401123A2 (hu)	2004-09-28
SK287235B6 (sk)	2010-04-07
TWI329512B (en)	2010-09-01
HUP0401123A3 (en)	2008-01-28
AR033468A1 (es)	2003-12-17
US8207159B2 (en)	2012-06-26
ATE378052T1 (de)	2007-11-15
IL158382A0 (en)	2004-05-12

Publication	Publication Date	Title
DK1572215T3 (da)	2010-01-11	Benzo[D]azepin-derivater til behandling af neurologiske lidelser
DK1474416T3 (da)	2008-01-14	Dihydrobenzodiazepin-2-on-derivater til behandlingen af neurologiske lidelser
DK1656347T3 (da)	2011-01-10	Substituerede indolderivater til farmaceutisk sammensætning til behandling af luftvejssygdomme
DK1339406T3 (da)	2004-09-27	Piperazinderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf til behandling af lidelser i centralnervesystemet
DK1562932T3 (da)	2007-08-13	4 tetrazolyl-4-phenylpiperidinderivater til behandling af smerter
DK1425001T3 (da)	2009-04-14	Phenethanolaminderivater til behandling af respiratoriske sygdomme
DK1343773T3 (da)	2007-02-05	Thiazolderivater til behandling af PPAR-beslægtede forstyrrelser
DK1282616T3 (da)	2004-09-20	Hydroxyphenylpiperidin-4-ylidenmethylbenzamidderivater til behandling af smerter
DK1381351T3 (da)	2004-11-29	Fremgangsmåde til kontinuerlig fremstilling af inhalerbare medikamenter
DK1491212T3 (da)	2012-10-29	Middel til behandling af søvnforstyrrelser
NO20034864D0 (no)	2003-10-31	Preparat for behandling av legemiddelindusert forstoppelse med 15-keto-prostaglandiner
DK1667967T3 (da)	2012-10-08	Fremgangsmåde til fremstilling af 2-oxo-1-pyrrolidin-derivater
DK1200081T3 (da)	2006-12-27	Anvendelse af escitalopram til behandling af generaliseret angstlidelse
DE50305374D1 (de)	2006-11-23	Neue prodrugs von 1-methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(n -2-pyridil-n-2-hydroxycarbonylethyl)-amid, ihre herstellung und ihre verwendung als arzneimittel
DK1344526T3 (da)	2008-09-15	Midler til forebyggelse/behandling af inflammatoriske luftvejslidelser
DK1383507T3 (da)	2008-03-17	Anvendelse af galanthamin til behandling af sygdomssymptomer i det centrale nervesystem på grund af intoxikationer med psykotrope substanser
DK1257278T3 (da)	2006-06-12	Anvendelse af mirtazapin til behandling af sövnforstyrrelser
DK1841433T3 (da)	2012-01-16	Præparat til behandling af lidelser i centralnervesystemet
DK1309322T3 (da)	2006-10-23	Anvendelse af 3-benzoylphenyleddikesyrederivater til behandling af retinale lidelser
DK1656365T3 (da)	2009-09-14	Fremgangsmåde til fremstilling af enantiomerisk rent mirtazapin
NO20032156L (no)	2003-05-13	Behandling av angstforstyrrelser
DK1351697T3 (da)	2014-01-20	Lægemiddel til fremme af regenerationen af væv
NO20034741D0 (no)	2003-10-23	Anvendelse av desoksypeganin for behandling av sykdomsforeteelser i det sentrale nervesystem grunnet forgiftning med psykotropiske substanser
AU2002308148A1 (en)	2003-04-17	Utilization of galanthamine for the treatment of pathologies of the central nervous system owing to intoxications with psychotropic substances
NO20030717D0 (no)	2003-02-14	Forbindelser for behandling av avhengighetsforstyrrelser